American Travelers Seek Cheaper Prescription Drugs In Mexico And Beyond

NPR, February 11, 2019
by Bram Sable-Smith

[...] The U.S. government estimates that close to 1 million people in California alone cross to Mexico annually for health care, including to buy prescription drugs. And between 150,000 and 320,000… Read More

Trump Highlights Health Agenda With Vow To Lower ‘Unfair’ Drug Prices

Kaiser Health News, February 6, 2019
by Julie Rovner

It was not the centerpiece, but health was a persistent theme in President Donald Trump’s State of the Union address at the Capitol on Tuesday night. Although the administration has focused more… Read More

Petrie-Flom Center Seeks RA for Project on Drug Pricing

Petrie-Flom Center, Applications due January 25!

Call for Applications: Research Assistant, Drug Pricing in the U.S. and GloballyThe Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School seeks a Research Assistant… Read More

Call for Applications: Research Assistant, Drug Pricing in the U.S. and Globally
Petrie-Flom Center, Harvard Law School

Deadline: January 25, 2019

Description:The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School seeks a current Harvard graduate student to serve as Research Assistant in support of the… Read More

Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment

Kaiser Health News, January 8, 2019
by Liz Szabo

Hoping to earn its share of the $3.5 trillion health care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to… Read More

Prescription Drug Costs Driven By Manufacturer Price Hikes, Not Innovation

NPR, January 7, 2019
by Alison Kodjak

The skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently… Read More

GlaxoSmithKline and Pfizer to Merge Consumer Health Units

New York Times, December 19, 2018
by Jamie Condliffe

GlaxoSmithKline and Pfizer plan to merge their consumer-health divisions in a joint venture that the companies said would be the world’s largest maker of over-the-counter products like pain relievers,… Read More

Set It and Forget It - How Better Contraception Could Be a Key to Reducing Poverty

New York Times, December 18, 2018
by Margot Sanger-Katz

When a woman of childbearing age goes to the doctor in most places, she gets standard queries about her smoking, drinking, seatbelt use and allergies. In Delaware, she is now also asked: “Do you… Read More

Investigation of generic ‘cartel’ expands to 300 drugs

Washington Post, December 9, 2018
by Christopher Rowland

Executives at more than a dozen generic-drug companies had a form of shorthand to describe how they conducted business, insider lingo worked out over steak dinners, cocktail receptions and rounds of golf.… Read More

AVAILABLE FOR PRE-ORDER! Transparency in Health and Health Care in the United States

Cambridge University Press, Forthcoming June 2019
by Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar, and Barbara J. Evans (eds.)

This edited volume stems from the Petrie-Flom Center’s 2017 annual conference, which brought together leading experts to reach better understandings of this health policy buzzword, recognizing… Read More

The Amount Americans Spend On Healthcare Is Still Growing, But More And More Slowly

Forbes, December 6, 2018
by Ellie Kincaid

The amount of money spent on healthcare in America is still growing, but at a slower rate than recent years, according to the U.S. government’s annual account. Americans spent $3.5 trillion… Read More

Drug Maker Pays $360 Million to Settle Investigation Into Charity Kickbacks

New York Times, December 6, 2018
by Katie Thomas

The drug maker Actelion Pharmaceuticals has agreed to a $360 million settlement stemming from an investigation into whether the company illegally funneled kickbacks through a patient-assistance charity, federal… Read More

Obamacare’s Looking So Good Insurers Are Fighting To Sell It

Forbes, November 19, 2018
by Bruce Japsen

News last week that Oscar Health filed a federal lawsuit accusing Florida Blue of a “monopoly” in selling individual health coverage under the Affordable Care Act is the latest signal… Read More

Limiting State Flexibility in Drug Pricing

NEJM, September 13, 2018
by Nicholas Bagley and Rachel E. Sachs (Academic Fellow Alumna)

From the article:  Throughout the United States, escalating drug prices are putting immense pressure on state budgets. Several states are looking for ways to push back. Last year, Massachusetts asked… Read More

Are Fraud and Abuse Laws Stifling Value-Based Care?

NEJM Catalyst , September 12, 2018
by Carmel Shachar (Executive Director)

From the article:  While health care delivery and financing should not be a free-for-all, designing the exemptions to explicitly conform to specific regulatory programs does not best serve the system.… Read More

Drug Pricing Policy

Health Affairs Blog, August 14, 2018
by Rachel E. Sachs (Academic Fellow Alumna)

From the post:  Last Tuesday, the Centers for Medicare and Medicaid Services (CMS) took its latest action in the area of drug pricing. CMS gave Medicare Advantage (MA) plans the ability… Read More

The Trump admin has another pretty good, pretty modest plan to lower drug costs

Vox, August 13, 2018
by Dylan Scott, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “My concern is that once again, the administration’s rhetoric is out of step with its actual policy moves,” Sachs said. “The administration is promoting this move… Read More

Perspective: Will Courts Allow States to Regulate Drug Prices?

NEJM, August 8, 2018
by Christopher Robertson (Academic Fellow Alumnus)

From the article: Pharmaceuticals are consuming increasingly large portions of U.S. state budgets, and high prices are preventing patients from getting, and adhering to, essential medicines. In mid-May… Read More

Report blames gaming of patent system for high drug prices

Med City News, August 9, 2018
by Alaric Dearment, quoting W. Nicholson Price II (Academic Fellow Alumnus)

[...] The report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices,” was released last week by the nonprofit Initiative… Read More

CMS’ plan to lower drug spending in Medicare Advantage

Politico Pulse, August 8, 2018
by Brianna Ehley, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Some viewed the step as a bit of a letdown, since HHS Secretary Alex Azar has been touting more sweeping changes to drug prices in Medicare Part B, like letting the private sector insurance… Read More

To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream

Kaiser Health News, August 1, 2018
by Rachel Bluth, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: This isn’t the first time officials have suggested importing drugs from other countries to find better prices. Bills have been offered in Congress to allow it, and George… Read More

On the Human Right to Health

Human Rights, Democracy, and Legitimacy in a World of Disorder , 2018
by I. Glenn Cohen (Faculty Director)

Faculty Director I. Glenn Cohen has written a chapter in the fortchoming book "Human Rights, Democracy, and Legitimacy in a World of Disorder," (Cambridge University Press, edited by Silja… Read More

Medical Tourism: Once Ready for Takeoff, Now Stuck at the Gate

Managed Care, March 28, 2018
by Richard Mark Kirkner, quoting I. Glenn Cohen (Faculty Director)

From the article: Consultants predicted it would be a major business. Large employers and insurers were experimenting with it. But medical tourism has not lived up to the heady expectations. The ACA and… Read More